Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...
Pfizer will cut over 200 jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on ...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...
Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...
Pharmaceutical Technology on MSN
Pfizer plans job cuts in Switzerland to reduce expenses
Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.
Zacks.com on MSN
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.
Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback